Arrowhead Pharmaceuticals Set to Unveil Q3 Earnings with Analysts Predicting Strong 'Outperform' Rating

Arrowhead Pharmaceuticals (ARWR) will announce Q3 earnings on August 7th post-market, with analysts expecting an EPS of -$1.10 and revenue of $29.01 million. Historically, ARWR has only beaten EPS estimates 13% of the time and revenue expectations 38% of the time. Analysts set an average price target of $44.00, indicating a 169.77% upside from the current share price of $16.31. The consensus from 15 brokerage firms gives ARWR an average brokerage recommendation of 2.2, denoting an "Outperform" status.

Title: Arrowhead Pharmaceuticals (ARWR) Prepares for Q3 Earnings Report

Arrowhead Pharmaceuticals (ARWR) will announce its third-quarter earnings on August 7th post-market, following a cautious tone set by analysts. The company is expected to report an EPS of -$1.10 and revenue of $29.01 million, based on the average forecast of 14 analysts. Historically, ARWR has only beaten EPS estimates 13% of the time and revenue expectations 38% of the time, indicating a challenging quarter ahead.

Analysts have set an average price target of $44.00 for ARWR, which represents a 169.77% upside from the current share price of $16.31. This significant potential upside is reflected in the strong "Outperform" rating given by 15 brokerage firms, with an average recommendation score of 2.2. The consensus among analysts is that ARWR has strong upside potential, despite the challenging earnings expectations.

GuruFocus provides an estimated GF Value for ARWR of $40.01 over the next year, suggesting a robust 145.31% upside from the present price of $16.31. This metric, calculated by considering historical trading multiples, past growth, and future business performance estimates, underscores the potential value in ARWR.

In addition to earnings, ARWR has been making strategic moves in the market. Recently, Sanofi has paid $130 million upfront for the China rights to Arrowhead’s rare metabolic disease treatment plozasiran, which is awaiting approval by Chinese regulators. This deal includes potential milestone payments of up to $265 million, reflecting the significant potential of the drug in the Chinese market. Plozasiran, an RNAi therapeutic, has shown promising results in phase 3 trials, reducing triglycerides by up to 80% in patients with familial chylomicronemia syndrome (FCS).

As ARWR prepares for its Q3 earnings report, investors will be closely watching the company’s performance and the potential impact of its strategic partnerships and pipeline developments. The upcoming earnings announcement will provide further insights into the company’s financial health and future prospects.

References:
[1] https://www.gurufocus.com/news/3042761/arrowhead-pharmaceuticals-arwr-prepares-for-q3-earnings-report
[2] https://www.fiercebiotech.com/biotech/sanofi-pens-395m-china-pact-arrowhead-metabolic-med-awaiting-approval-decision
[3] https://finance.yahoo.com/quote/ARWR/
[4] https://pharmaphorum.com/news/sanofi-grabs-chinese-rights-arrowhead-rare-disease-drug